Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Patent
1998-07-14
1999-04-06
Wilson, James O.
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
544317, 544310, 544212, 544276, 544277, 544313, 544229, 549310, A61K 3170, A61K 31505
Patent
active
058920250
ABSTRACT:
A process for the resolution of a racemic mixture of nucleoside enantiomers that includes the step of exposing the racemic mixture to an enzyme that referentially catalyzes a reaction in one of the enantiomers. The nucleoside enantiomer (-)-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane is an effective antiviral agent against HIV, HBV, and other viruses replicating in a similar manner.
REFERENCES:
patent: 3116268 (1963-12-01), Farago
patent: 3116282 (1963-12-01), Hunter
patent: 3553192 (1971-01-01), Gauri
patent: 4000137 (1976-12-01), Dvonch et al.
patent: 4336381 (1982-06-01), Nagata et al.
patent: 4861759 (1989-08-01), Hiroaki et al.
patent: 4879277 (1989-11-01), Mitsuya et al.
patent: 4900828 (1990-02-01), Belica et al.
patent: 4916122 (1990-04-01), Chu et al.
patent: 4963533 (1990-10-01), de Clercq et al.
patent: 4968674 (1990-11-01), Taniyama et al.
patent: 5011774 (1991-04-01), Farina et al.
patent: 5041449 (1991-08-01), Belleau et al.
patent: 5047407 (1991-09-01), Belleau et al.
patent: 5059690 (1991-10-01), Zahler et al.
patent: 5071983 (1991-12-01), Koszalka et al.
patent: 5089500 (1992-02-01), Daluge
patent: 5151426 (1992-09-01), Belleau et al.
patent: 5179104 (1993-01-01), Chu et al.
patent: 5185437 (1993-02-01), Kozalka et al.
patent: 5204466 (1993-04-01), Liotta et al.
patent: 5210085 (1993-05-01), Liotta et al.
patent: 5215971 (1993-06-01), Datema et al.
patent: 5234913 (1993-08-01), Furman, Jr. et al.
patent: 5246924 (1993-09-01), Fox et al.
patent: 5248776 (1993-09-01), Chu et al.
patent: 5270315 (1993-12-01), Belleau et al.
patent: 5276151 (1994-01-01), Liotta
patent: 5409906 (1995-04-01), Datema et al.
patent: 5432165 (1995-07-01), Adair et al.
patent: 5444063 (1995-08-01), Schinazi
patent: 5446029 (1995-08-01), Eriksson et al.
patent: 5466806 (1995-11-01), Belleau et al.
patent: 5486520 (1996-01-01), Belleau et al.
patent: 5521161 (1996-05-01), Malley et al.
patent: 5532246 (1996-07-01), Belleau et al.
patent: 5538975 (1996-07-01), Dionne
patent: 5539116 (1996-07-01), Liotta et al.
patent: 5587480 (1996-12-01), Belleau et al.
patent: 5618820 (1997-04-01), Dionne
patent: 7686617 (1996-07-01), Cheng
patent: 7718806 (1991-06-01), Cheng
patent: 7785545 (1991-10-01), Cheng
Allenmark, S. G., (eds.), Chromatographic Enantioseparation: Methods and Applications, Wiley & Sons, Brisbane (1988).
Armstrong, D. W., "Chiral Stationary Phases for High Performance Liquid Chromatographic Separation of Enantiomers: A Mini-Review," J. of Liquid Chromatography, 7(S-2), 353-376 (1984).
Balzarini, J., et al., "Synthesis and Antiviral Activity of the Enantiomeric Forms of Carba-5-Iodo-2'-Deoxyuridine and Carba-(E)-5-(2-Bromovinyl)-2'-Deoxyuridine," J. Med. Chem., 1989, vol. 32, No. 8, pp. 1861-1865.
Coates, J. A. V., et al., "The Separated Enantiomers of 2'-Deoxy-3'-Thiacytidine (BCH-189) Both Inhibit Humin Immunodeficiency Virus Replication In Vitro," Antimicrobial Agents and Chemotherapy, vol. 36, No. 1, Jan. 1992, pp. 202-205.
Dappen, R., et al., "Applications and Limitations of Commercially Availabel Chiral Stationary Phases for High Performance Liquid Chromatography," J. Chromatography 373:1-20 (1986).
Forsman, U., "Enantiomeric Resolution of an Optically Active Guanine Derivative By High Performance Liquid Chromatography with Phenylalanine-CU (II) in the Mobile Phase," J. of Chromatography, 303 (1984), pp. 217-221.
Giddings, J. C., (ed.), Advances in Chromatography, vol. 27, Marcel Dekker, Inc. New York, 1987, pp. 73-127.
Hinze, W. L., "Liquid Chromatographic Separation of Enantiomers Using a Chiral .beta.-Cyclodextrin-Bonded Stationary Phase and Conventional Aqueous-Organic Mobile Phases," Anal. Chem., 1985, 57, pp. 237-242.
Holy, A., "Syntheses of Enantiomeric N-(3-Hydroxy-2-Phosphonomethoxypropyl) Derivatives of Purine and Pyrimidine Bases,"Collect. Czech. Chem. Commun., vol. 58, 1992, pp. 649-675.
Holy, A., "New Synthesis of Ribonucleoside Carbocyclic Analogues," Collection Czechosiov. Chem. Commun., vol. 41, 1976, pp. 2096-2109.
Mansuri, M. M., et al, "Preparation of the Geometric Isomers of DDC, DDA, D4C, and D4T as Potential Anti-HIV Agents," Bioorgan. and Med. Chem. Lett., 1(1):65-68 (1991).
Schinazi, R. F., "Activities of the Four Optical Isomers of 2',3'-Dideoxy-3-Thiacytidine (BCH-189) Against Human Immunodeficiency Virus Type 1 in Human Lymphocytes," Antimicrob. Agents and Chemotherapy, 36(3): 672-676, 1992.
Thomas, S.B., et al., "Preparative Separation and Analysis of the By Ligand-Exchange High-Performance Liquid Chromatography," J. Chromatography, 586, (1991), pp. 265-270.
Wainer, I. W., "A Practical Guide to the Selection and Use of HPLC Chiral Stationary Phases," 1988, J. T Baker Inc., Phillipsburg, NJ, pp. 1-38.
Wainer, I. W., "Drug Analysis Using High Performance Liquid Chromatographic (HPLC) Chiral Stationary Phases: Where to Begin and Which to Use," Chiral Separations, Plenum Press, New York, 1987, pp. 11-21.
Wainer, I.W., "Proposal for the Classification of High Performance Liquid Chromatographic Chiral Stationary Phases: How to Choose the Right Column," Trends in Analytical Chemistry, vol. 6, No. 5, 1987, pp. 125-134.
Abobo, et al., Pharmacokinetics of 2',3'-Dideoxy-5-fluoro-3'-thiacytidine in Rats," J. of Pharmaceutical Sciences, 83(1):96-99 (1994).
Agrant and Biedermann, "Intellectual Property and Chirality: Patentability of Enantiomers of Racemic Drugs in a Racemic Switch Scenario," Institute for Advanced Studies at The Hebrew University of Jerusalem, 8th Chirality Conference, Edinburgh, UK (Jul. 2, 1996).
Agrofogilo, et al., "Synthesis of Carbocyclic Nucleosides," Tetrahedron 50(36):10611-10670 (1994).
Asseline, et al., "Synthesis and physicochemical properties of oligonucleotides built with either .alpha.-L or .beta.-L nucleotides units and covalently linked to an acridine derivative," Nucl. Acids Res., 19(15):4067-4074 (1991).
Balzarini, J., et al., "Potent and Selective Anti-HTLV-III/LAV Activity of 2',3'-Dideoxycytidinene, the 2',3'-Unsaturated Derivative of 2',3'-Dideoxycytidine," Biochemical and Biophysical Research Communications, 140(2): 735-742 (1986).
Balzarini, et al., "2'-3'-Didehydro-2'-3'-Dideoxy-5-Chlorocytidine is a Selective Anti--Retrovirus Agent," Biochem. and Biophys. Res. Comm., 164(3):1190-1197 (1989).
Balzarini, et al., "5-Chloro-Substituted Derivatives of 2'-3'-Didehydro-2'-3'-Dideoxyuridine, 3'-Fluoro-2'-3'-Dideoxyuridine and 3'-Azido-2'-3'-Dideoxyuridine as Anti-HIV Agents," Biochemical Pharmacol., 38(6):869-874 (1989).
Baschang, et al., "The enantiomers of 1.beta.-adenyl-2.alpha. hydroxy-3.beta.-(hydroxymenthyl)cyclobutane," Tetrahedron:Asymmetry, 3(2):193-6 (1992).
Beach, J.W., et al., "Synthesis of Enantiomerically Pure Antiviral Agent Against Hepatitis B Virus (HBV) and Human Immunodeficiency Virus (HIV)," J. Org. Chem., 57:2217-2219 (1992).
Belleau, B., et al., "Design and Activity of a Novel Class of Nucleoside Analogs Effective Against HIV-1," International Conference on AIDS, Montreal, Quebec, Canada, Jun. 4-9, 1989.
Biron, et al., "Anti-HIV Activity of the combination of Didanosine and Hydroxyurea in HIV-1-Infected Individuals," J. of Acquired Immune Deficiency Syndromes and Human Retrovirology, 10:36-40 (1995).
Borthwick, et al., "Synthesis and Enzymatic Resolution of Carbocyclic 2'-Ara-Fluoro--Guanosine: A Potent New Anti-Herpetic Agent," J. Chem. Soc. Commun., vol. 10. pp. 656-658 (1988).
Bouffard, D.Y., et al., "Kinetic Studies on 2'2'-Difluorodeoxycytidine(Gemcitabine) with Purified Human Deoxycytidine Kinase and Cytidine Deaminase," Biochem. Pharmacol., 45(9):1857-1861 (1993).
Carter, et al., "Activities of (-)-Carbovir and 3'-Azido-3'-Deoxythymidine Against Human Immunodeficiency Virus In Vitro," Antimicrobial Agents and Chemotherapy, 34(6):1297-1300 (1990).
Chang, C-N., et al., "Biochemical Pharmacology of (+) and (-)-2',3'-Dideoxy-3'-Thiacytidine as Anti-Hepatitis B Virus Agents," J. Biol. Chem., 267(31):22414-22420 (1992).
Chang, Chien-Neng, et al., "Deoxycytidine Deaminase-resistant Steroisomer Is the Active Form of (.+-.)-2',3'-Dideoxy-3'-thiacytidine in the Inhibition of Hepatitis B Virus Re
Choi Woo-Baeg
Liotta Dennis C.
Schinazi Raymond F.
Emory University
Haley Jacqueline
Knowles Sherry M.
Wilson James O.
LandOfFree
Method of resolution and antiviral activity of 1,3-oxathiolane n does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of resolution and antiviral activity of 1,3-oxathiolane n, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of resolution and antiviral activity of 1,3-oxathiolane n will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1372457